Scarica l'app Stockscreener
529.14
2.10%
10.87
Dopo l'orario di chiusura:
529.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript - AOL.com
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation Completes Enrollment Of TETON-PPF Study Of Inhaled Treprostinil For Progressive Pulmonary Fibrosis - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Potential 30% Upside Captivates Investors - DirectorsTalk Interviews
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
Mid Cap Index Fund's United Therapeutics Corp(UTHR) Holding History - GuruFocus
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock By Investing.com - Investing.com South Africa
United Therapeutics CEO Martine Rothblatt sells $4.79m in stock - Investing.com
United Therapeutics (UTHR) CEO Rothblatt exercises 9,500 options and sells 9,500 shares via 10b5-1 plan - Stock Titan
UTHR|United Therapeutics Corp|Price:499.730|Chg%:-1.540 - TradingKey
United Therapeutics CEO Rothblatt sells $4.89m in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt sells $4.89m in stock - Investing.com
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics Corp (UTHR) CEO’s trust sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) Stock Looks Undervalued Despite Fresh NDA Filings - simplywall.st
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play - ChartMill
United Therapeutics Corp (UTHR) CEO trades 9,500 shares after option exercise - Stock Titan
UNITED THERAPEUTICS CORP (UTHR.MX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
United Therapeutics chairperson & CEO sells $5.05m in stock By Investing.com - Investing.com Australia
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics chairperson & CEO sells $5.05m in stock - Investing.com
Baylor College of Medicine strikes multimillion-dollar deal with United Therapeutics for transplant center - The Business Journals
United Therapeutics (UTHR) CEO trades 9,500 shares under 10b5-1 option plan - Stock Titan
Assenagon Asset Management S.A. Purchases 37,355 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics (NASDAQ:UTHR) Sees Strong Trading VolumeShould You Buy? - MarketBeat
United Therapeutics EVP & general counsel Mahon sells $4.29m in shares - Investing.com South Africa
United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics Balances Tyvaso Woes With Pipeline Wins - The Globe and Mail
United Therapeutics (UTHR) counsel exercises options, sells 8,300 shares - Stock Titan
United Therapeutics Corp (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Royal Bank Of Canada Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price - marketbeat.com
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark - Yahoo Finance
United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highligh - GuruFocus
United Therapeutics Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
BofA cuts United Therapeutics stock price target on Tyvaso sales - Investing.com
United Therapeutics Corp (UTHR) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress ... - Yahoo Finance
United Therapeutics Q2 Earnings Call Highlights - MarketBeat
United Therapeutics Corporation (UTHR) options chain - Yahoo Finance Australia
United Therapeutics (NASDAQ:UTHR) Announces Earnings Results - MarketBeat
Earnings call transcript: United Therapeutics posts Q2 2026 EPS beat, revenue miss - Investing.com
United Therapeutics Q2 2026 slides: pipeline advances amid revenue headwinds - Investing.com
United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Is United Therapeutics Corp (UTHR) Overvalued After Q2 Earnings - GuruFocus
United Therapeutics (UTHR) Q2 Earnings Surpass Estimates - Yahoo Finance
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales - Yahoo Finance
United Therapeutics reports Q2 2026: Revenues $783.3M, Net Income $333.0M, EPS $7.27 diluted - TradingView
United Therapeutics 2026: Revenue $783.3M, EPS $7.27— 10-Q Summary - TradingView
United Therapeutics: Q2 Earnings Snapshot - Barchart.com
0.46%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):